메뉴 건너뛰기




Volumn 4, Issue 6, 2008, Pages 1165-1175

Treatment of severe psoriasis with infliximab

Author keywords

Co morbidities; Infliximab; Pathogenesis; Psoriasis; Treatment

Indexed keywords

CENTOCOR; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RETINOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 61549124792     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3094     Document Type: Review
Times cited : (12)

References (87)
  • 1
    • 20244376625 scopus 로고    scopus 로고
    • Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial
    • Antoni C, Kavanaugh A, Kirkham B, et al. 2005a. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial. Arthritis Rheum, 52:1227-36.
    • (2005) Arthritis Rheum , vol.52 , pp. 1227-1236
    • Antoni, C.1    Kavanaugh, A.2    Kirkham, B.3
  • 2
    • 19044382942 scopus 로고    scopus 로고
    • Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial
    • Antoni C, Krueger GG, de Vlam K, et al. 2005b. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis, 64:1150-75.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1150-1175
    • Antoni, C.1    Krueger, G.G.2    de Vlam, K.3
  • 3
    • 0033546665 scopus 로고    scopus 로고
    • The lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS: Results of a randomised. placebo controlled multicentre study
    • Arnason BGW 1999. The lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralisation in MS: results of a randomised. placebo controlled multicentre study. Neurology, 53:457-65.
    • (1999) Neurology , vol.53 , pp. 457-465
    • Arnason, B.G.W.1
  • 4
    • 33845660797 scopus 로고    scopus 로고
    • Individualized monitoring of drug bioavailability and immogenicity in rheumatoid arthritis patients treated with tumour necrosis factor alpha inhibitor infliximab
    • Bendtzen K, Geborek P, Svenson M et al. 2006. Individualized monitoring of drug bioavailability and immogenicity in rheumatoid arthritis patients treated with tumour necrosis factor alpha inhibitor infliximab. Arthritis Rhem, 54:3782-89.
    • (2006) Arthritis Rhem , vol.54 , pp. 3782-3789
    • Bendtzen, K.1    Geborek, P.2    Svenson, M.3
  • 5
    • 3042703125 scopus 로고    scopus 로고
    • Treatment of recalcitrant pustular psoriasis with infliximab: Effective reduction of chemokine expression
    • Benoit S, Toksoy A, Brocker EB et al. 2004. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol, 150:1009-12.
    • (2004) Br J Dermatol , vol.150 , pp. 1009-1012
    • Benoit, S.1    Toksoy, A.2    Brocker, E.B.3
  • 6
    • 17844386820 scopus 로고    scopus 로고
    • Remission and time of resolution of nail psoriasis during infliximab therapy
    • Bianchi L, Bergamin A, de Felice C, et al. 2005. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol, 52:736-7.
    • (2005) J Am Acad Dermatol , vol.52 , pp. 736-737
    • Bianchi, L.1    Bergamin, A.2    de Felice, C.3
  • 7
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-95.
    • (2006) JAMA , vol.295 , pp. 2275-2295
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3
  • 8
    • 0036637636 scopus 로고    scopus 로고
    • Therapeutic Management of psoriasis
    • Bundu-Kamara S. 2002. Therapeutic Management of psoriasis Hospital Pharmacist 9:191-99.
    • (2002) Hospital Pharmacist , vol.9 , pp. 191-199
    • Bundu-Kamara, S.1
  • 9
    • 33744801949 scopus 로고    scopus 로고
    • Psoriasis: A general overview
    • Burd RM. 2006. Psoriasis: a general overview. Br J Hosp Med, 67:259-62.
    • (2006) Br J Hosp Med , vol.67 , pp. 259-262
    • Burd, R.M.1
  • 10
    • 61549106416 scopus 로고    scopus 로고
    • Immunological evidence for increasing reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis: FC-13
    • Camp RDR, El-Rachkidy RG, Young HS, et al. 2006. Immunological evidence for increasing reactivity to secreted Streptococcus pyogenes proteins in chronic plaque psoriasis: FC-13. Br J Dermatol, 154(Suppl 1):5.
    • (2006) Br J Dermatol , vol.154 , Issue.SUPPL. 1 , pp. 5
    • Camp, R.D.R.1    El-Rachkidy, R.G.2    Young, H.S.3
  • 11
    • 34547774225 scopus 로고    scopus 로고
    • Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis
    • Capon F, Di Meglio P, Szaub J, et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet, 122(2):201-6.
    • (2007) Hum Genet , vol.122 , Issue.2 , pp. 201-206
    • Capon, F.1    Di Meglio, P.2    Szaub, J.3
  • 12
    • 2542445474 scopus 로고    scopus 로고
    • A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    • Carlin CS, Feldman SR, Krueger JG, et al. 2004. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50:859-66.
    • (2004) J Am Acad Dermatol , vol.50 , pp. 859-866
    • Carlin, C.S.1    Feldman, S.R.2    Krueger, J.G.3
  • 13
    • 15744398663 scopus 로고    scopus 로고
    • Combining traditional agents and biologies for treatment of psoriasis
    • Cather J, Menter A. 2005. Combining traditional agents and biologies for treatment of psoriasis. Semin Cut Med Surg, 24:37-45.
    • (2005) Semin Cut Med Surg , vol.24 , pp. 37-45
    • Cather, J.1    Menter, A.2
  • 14
    • 61549130092 scopus 로고    scopus 로고
    • Centocor Inc. 2006. Remicade (infliximab) package insert: Chicago, II, USA available at
    • Centocor Inc. 2006. Remicade (infliximab) package insert: Chicago, II, USA available at www.gene.com/gene/products/information/pdf/ raptivaprescribing.pdf
  • 16
    • 47249159958 scopus 로고    scopus 로고
    • Psoriatic skin lesions induced by tumour necrosis factor antagonist therapy: A literature review and potential mechanisms of action
    • Collamer A, Guerrero KT, Henning JS, et al. 2008. Psoriatic skin lesions induced by tumour necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Care and Research, 57:996-1001.
    • (2008) Arthritis Care and Research , vol.57 , pp. 996-1001
    • Collamer, A.1    Guerrero, K.T.2    Henning, J.S.3
  • 17
    • 0035072326 scopus 로고    scopus 로고
    • Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci
    • Cookson WO. Ubhi B. Lawrence R et al. 2001. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nature Genetics, 27(4):372-3.
    • (2001) Nature Genetics , vol.27 , Issue.4 , pp. 372-373
    • Cookson, W.O.1    Ubhi, B.2    Lawrence, R.3
  • 18
    • 33750797800 scopus 로고    scopus 로고
    • Dixon W, Silman A. 2006. Is there an association between anti-TNF antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta analysis by Bongartz et al. Arthritis Res Ther, 8:11.
    • Dixon W, Silman A. 2006. Is there an association between anti-TNF antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta analysis by Bongartz et al. Arthritis Res Ther, 8:11.
  • 19
    • 34848839939 scopus 로고    scopus 로고
    • Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
    • Dixon WG, Symmons DP, Lunt M, et al. 2007. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Arthritis Rheum, 56:2896-904.
    • (2007) Arthritis Rheum , vol.56 , pp. 2896-2904
    • Dixon, W.G.1    Symmons, D.P.2    Lunt, M.3
  • 20
    • 33745544337 scopus 로고    scopus 로고
    • PSORS 1: Linking genetics and immunology
    • Elder JT. 2006. PSORS 1: linking genetics and immunology. J Invest Dermatol, 126:1205-6.
    • (2006) J Invest Dermatol , vol.126 , pp. 1205-1206
    • Elder, J.T.1
  • 22
    • 0000219334 scopus 로고    scopus 로고
    • Human ant-chimaeric antibody levels correlate with a lack of response and infusion reactions following infliximab therapy
    • abstract 364
    • Farrel RJ, Alsahli M, Falchuk KR, et al. 2001. Human ant-chimaeric antibody levels correlate with a lack of response and infusion reactions following infliximab therapy. Gastroenterology, 120(Suppl 1):A69 abstract 364.
    • (2001) Gastroenterology , vol.120 , Issue.SUPPL. 1
    • Farrel, R.J.1    Alsahli, M.2    Falchuk, K.R.3
  • 23
    • 14244250511 scopus 로고    scopus 로고
    • Psoriasis assessment tools in clinical practice
    • Feldman SR, Krueger GG. 2005. Psoriasis assessment tools in clinical practice. Ann Rheum Dis, 64(Suppl ii):65-8.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. II , pp. 65-68
    • Feldman, S.R.1    Krueger, G.G.2
  • 24
    • 21044440425 scopus 로고    scopus 로고
    • Infliximab results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial
    • Feldman SR, Gordon KB, Bala M, et al. 2005. Infliximab results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. J Am Acad Dermatol, 152:954-60.
    • (2005) J Am Acad Dermatol , vol.152 , pp. 954-960
    • Feldman, S.R.1    Gordon, K.B.2    Bala, M.3
  • 25
    • 18944404879 scopus 로고    scopus 로고
    • Current severe psoriasis and the rule of tens
    • Finlay AY 2005. Current severe psoriasis and the rule of tens. Br J Dermatol, 152:861-7.
    • (2005) Br J Dermatol , vol.152 , pp. 861-867
    • Finlay, A.Y.1
  • 26
    • 29144466801 scopus 로고    scopus 로고
    • Prevalence and treatment of psoriasis in the United Kingdom: A population - base study
    • Gelfland JM, Weinstein R, Porter SB, et al. 2005. Prevalence and treatment of psoriasis in the United Kingdom: a population - base study. Arch Dermatol, 141:1537-41.
    • (2005) Arch Dermatol , vol.141 , pp. 1537-1541
    • Gelfland, J.M.1    Weinstein, R.2    Porter, S.B.3
  • 27
    • 33749613119 scopus 로고    scopus 로고
    • Risk of myocardial infarction in patients with psoriasis
    • Gelfand JM, Neimann AL, Shin DB, et al. 2006. Risk of myocardial infarction in patients with psoriasis. JAMA, 296:1735-41.
    • (2006) JAMA , vol.296 , pp. 1735-1741
    • Gelfand, J.M.1    Neimann, A.L.2    Shin, D.B.3
  • 28
    • 0030826483 scopus 로고    scopus 로고
    • T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice
    • Gilhar A, David M, Ullman T, et al. 1997. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol, 109:283-8.
    • (1997) J Invest Dermatol , vol.109 , pp. 283-288
    • Gilhar, A.1    David, M.2    Ullman, T.3
  • 29
    • 39049173409 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor alpha therapy increases bodt weight in patients with chronic plaque psoriasis: A retrospective cohort study
    • Gisondi P, Cotena C, tessari G, et al. 2007. Anti-tumour necrosis factor alpha therapy increases bodt weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol, 22:341-4.
    • (2007) J Eur Acad Dermatol , vol.22 , pp. 341-344
    • Gisondi, P.1    Cotena, C.2    tessari, G.3
  • 30
    • 14244260176 scopus 로고    scopus 로고
    • Psoriatic arthritis: Epidemiology, clinical features, course and outcome
    • Gladman D, Antoni C, Mease P, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis, 64(Suppl 1):14-7.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. 1 , pp. 14-17
    • Gladman, D.1    Antoni, C.2    Mease, P.3
  • 31
    • 4644327125 scopus 로고    scopus 로고
    • Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomised double-blind, placebo-controlled trial
    • Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomised double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
    • (2004) J Am Acad Dermatol , vol.51 , pp. 534-542
    • Gottlieb, A.B.1    Evans, R.2    Li, S.3
  • 32
    • 0032806844 scopus 로고    scopus 로고
    • Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis?
    • Gudmundsdottir AS, Sigmundsdotir H, Sigurgeirsson B, et al. 1999. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Dermatol. 117:580-6.
    • (1999) Clin Exp Dermatol , vol.117 , pp. 580-586
    • Gudmundsdottir, A.S.1    Sigmundsdotir, H.2    Sigurgeirsson, B.3
  • 33
    • 30144436177 scopus 로고    scopus 로고
    • Anti-infiximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
    • Haraoui B, Cameron L, Ouellet M, et al. 2006. Anti-infiximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol, 33:31-6.
    • (2006) J Rheumatol , vol.33 , pp. 31-36
    • Haraoui, B.1    Cameron, L.2    Ouellet, M.3
  • 34
    • 19644364586 scopus 로고    scopus 로고
    • The benefit/risk profile of TNT - blocking agents: Findings of a concensus panel
    • Hochberg MC, Lebwohl MG, Plevy, et al. 2005. The benefit/risk profile of TNT - blocking agents: findings of a concensus panel. Semin Arthritis Rheum, 34:819-36.
    • (2005) Semin Arthritis Rheum , vol.34 , pp. 819-836
    • Hochberg, M.C.1    Lebwohl, M.G.2    Plevy3
  • 35
    • 33746972770 scopus 로고    scopus 로고
    • Pregnancy outcome in women who were exposed to anti-tumour necrosis factor agents: Results from a national population register
    • Hyrich KL, Symmons DPM, Watson KD, et al. 2006. Pregnancy outcome in women who were exposed to anti-tumour necrosis factor agents: results from a national population register. Arthritis Rheum, 54:2701-8.
    • (2006) Arthritis Rheum , vol.54 , pp. 2701-2708
    • Hyrich, K.L.1    Symmons, D.P.M.2    Watson, K.D.3
  • 36
    • 34147204834 scopus 로고    scopus 로고
    • Infliximab maintains a higher degree of clinical response through 1 year of treatment: Results from the IMPACT 2 trial
    • Kavanaugh A, Krueger GG, Bender A, et al. 2007. Infliximab maintains a higher degree of clinical response through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis, 66:498-505.
    • (2007) Ann Rheum Dis , vol.66 , pp. 498-505
    • Kavanaugh, A.1    Krueger, G.G.2    Bender, A.3
  • 37
    • 0036145337 scopus 로고    scopus 로고
    • The immunological basis for the treatment of psoriasis with new biological agents
    • Krueger JG. 2002. The immunological basis for the treatment of psoriasis with new biological agents. J Am Acad Dermatol, 46:1-23.
    • (2002) J Am Acad Dermatol , vol.46 , pp. 1-23
    • Krueger, J.G.1
  • 38
    • 0037672879 scopus 로고    scopus 로고
    • Case reports of heart failure after therapy with tumour necrosis factor antagonist
    • Kwon HJ, Cote TR, Cuffe MS, et al. 2003. Case reports of heart failure after therapy with tumour necrosis factor antagonist. Ann Intern Med, 138:807-11.
    • (2003) Ann Intern Med , vol.138 , pp. 807-811
    • Kwon, H.J.1    Cote, T.R.2    Cuffe, M.S.3
  • 39
    • 0037420518 scopus 로고    scopus 로고
    • Psoriasis
    • Lebowohl M. 2003. Psoriasis. Lancet, 361:1197-204.
    • (2003) Lancet , vol.361 , pp. 1197-1204
    • Lebowohl, M.1
  • 40
    • 30444432567 scopus 로고    scopus 로고
    • Obesity, smoking and psoriasis
    • Lebowohl M, Callen JP. 2006. Obesity, smoking and psoriasis. JAMA, 295:208-10.
    • (2006) JAMA , vol.295 , pp. 208-210
    • Lebowohl, M.1    Callen, J.P.2
  • 41
    • 49749131222 scopus 로고    scopus 로고
    • Review and expert opinion on the prevention and treatment of infliximab-related infusion reactions
    • Lecluse LLA, Piskin G, Mekkes JR, et al. 2008. Review and expert opinion on the prevention and treatment of infliximab-related infusion reactions. Br J Dermatol, 159:527-36.
    • (2008) Br J Dermatol , vol.159 , pp. 527-536
    • Lecluse, L.L.A.1    Piskin, G.2    Mekkes, J.R.3
  • 42
    • 1842450793 scopus 로고    scopus 로고
    • 10 years experience of the Dermatology Life Quality index (DLQI)
    • Lewis V, Finlay AY. 2004. 10 years experience of the Dermatology Life Quality index (DLQI) J Invest Dermatol Symp Proc, 9:169-8.
    • (2004) J Invest Dermatol Symp Proc , vol.9 , pp. 169-178
    • Lewis, V.1    Finlay, A.Y.2
  • 43
    • 33746443001 scopus 로고    scopus 로고
    • Life threatening pustular and eythrodermic psoriasis responding to infliximab
    • Lewis TG, Tuchinda C, Lim HW, et al. 2006. Life threatening pustular and eythrodermic psoriasis responding to infliximab. J Drugs Dermatol, 5:546-8.
    • (2006) J Drugs Dermatol , vol.5 , pp. 546-548
    • Lewis, T.G.1    Tuchinda, C.2    Lim, H.W.3
  • 45
    • 33846592386 scopus 로고    scopus 로고
    • Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
    • Mackkey AC, Green L, Liang LC, et al. 2007. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 44:265-7.
    • (2007) J Pediatr Gastroenterol Nutr , vol.44 , pp. 265-267
    • Mackkey, A.C.1    Green, L.2    Liang, L.C.3
  • 46
    • 0031660364 scopus 로고    scopus 로고
    • Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis
    • Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum, 41:1552-63.
    • (1998) Arthritis Rheum , vol.41 , pp. 1552-1563
    • Maini, R.N.1    Breedveld, F.C.2    Kalden, J.R.3
  • 47
    • 1842663219 scopus 로고    scopus 로고
    • Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients
    • Mallbris L, Arke O, Granath F, et al. 2004. Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients. Eur J Epidemiol, 19:225-30.
    • (2004) Eur J Epidemiol , vol.19 , pp. 225-230
    • Mallbris, L.1    Arke, O.2    Granath, F.3
  • 48
    • 15044361734 scopus 로고    scopus 로고
    • Psoriasis phenotype at disease onset: Clinical characterisation of 400 adult cases
    • Mallbris L, Larsson P, Bergqvist S, et al. 2005. Psoriasis phenotype at disease onset: clinical characterisation of 400 adult cases. J Invest Dermatol, 124:499-504.
    • (2005) J Invest Dermatol , vol.124 , pp. 499-504
    • Mallbris, L.1    Larsson, P.2    Bergqvist, S.3
  • 50
    • 11144277873 scopus 로고    scopus 로고
    • Diagnosis and treatment of psoriatic arthritis
    • Mease P, Goffe B. 2005. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol, 52:1-19.
    • (2005) J Am Acad Dermatol , vol.52 , pp. 1-19
    • Mease, P.1    Goffe, B.2
  • 51
    • 14244269341 scopus 로고    scopus 로고
    • Psoriatic arthritis assessment tools in clinical trials
    • Mease PJ, Antoni CE, Gladman DD et al. 2005. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis, 64:ii49-ii54.
    • (2005) Ann Rheum Dis , vol.64
    • Mease, P.J.1    Antoni, C.E.2    Gladman, D.D.3
  • 52
    • 61549105129 scopus 로고    scopus 로고
    • Quality of life issues in psoriasis and psoriatic arthritis:Outcome measure and therapies from a dermatological perspective
    • Mease PJ, Menter A. 2006. Quality of life issues in psoriasis and psoriatic arthritis:Outcome measure and therapies from a dermatological perspective. J Am Acad Dermatol, 50:859-66.
    • (2006) J Am Acad Dermatol , vol.50 , pp. 859-866
    • Mease, P.J.1    Menter, A.2
  • 53
    • 1342346479 scopus 로고    scopus 로고
    • Successfal treatment of pediatric psoriasis with infliximab
    • Menter M, Alan MD, Cush JM, et al. 2004. Successfal treatment of pediatric psoriasis with infliximab. Paed Dermatol, 21:87-8.
    • (2004) Paed Dermatol , vol.21 , pp. 87-88
    • Menter, M.1    Alan, M.D.2    Cush, J.M.3
  • 54
    • 33845692734 scopus 로고    scopus 로고
    • Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. J Am Acad Dermatol, 56:31.e1-15.
    • Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. J Am Acad Dermatol, 56:31.e1-15.
  • 55
    • 0035674613 scopus 로고    scopus 로고
    • Demyelination occurring during anti-tumour necrosis factor alpha for inflammatory arthritidies
    • Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumour necrosis factor alpha for inflammatory arthritidies. Arthritis Rheum, 44:2862-9.
    • (2001) Arthritis Rheum , vol.44 , pp. 2862-2869
    • Mohan, N.1    Edwards, E.T.2    Cupps, T.R.3
  • 57
    • 39949085766 scopus 로고    scopus 로고
    • Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque type psoriasis: Report on five cases
    • Mossner R, Thaci D, Mohr J, et al. 2008. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque type psoriasis: report on five cases. Arch Dermatol Res, 30:101-5.
    • (2008) Arch Dermatol Res , vol.30 , pp. 101-105
    • Mossner, R.1    Thaci, D.2    Mohr, J.3
  • 58
    • 22144490239 scopus 로고    scopus 로고
    • Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: Results from an Italian case control study
    • Naldi L, Chatenoud L, Linder D, et al. 2005. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case control study. J Inves Dermatol, 125:61-7.
    • (2005) J Inves Dermatol , vol.125 , pp. 61-67
    • Naldi, L.1    Chatenoud, L.2    Linder, D.3
  • 59
    • 61549130736 scopus 로고    scopus 로고
    • Infliximab for the treatment of adults with psoriasis- Final Scope
    • technology appraisal [online, URL
    • NICE. 2006. Infliximab for the treatment of adults with psoriasis- Final Scope. NICE single technology appraisal [online]. URL: www.nice.org.uk/ TA134.
    • (2006) NICE single
  • 60
    • 0025831330 scopus 로고    scopus 로고
    • The cytokine network in psoriasis
    • Nickoloff BJ. 1999. The cytokine network in psoriasis. Arch Dermatol, 127:871-84.
    • (1999) Arch Dermatol , vol.127 , pp. 871-884
    • Nickoloff, B.J.1
  • 61
    • 33751524052 scopus 로고    scopus 로고
    • Anti-TNF alpha in childhood pustular psoriasis
    • Pereira TM, Vieira AP, Fernandes JC, et al. 2006. Anti-TNF alpha in childhood pustular psoriasis. Dermatology, 213:350-2.
    • (2006) Dermatology , vol.213 , pp. 350-352
    • Pereira, T.M.1    Vieira, A.P.2    Fernandes, J.C.3
  • 62
    • 0032761861 scopus 로고    scopus 로고
    • Excess mortality related to alcohol and smoking among hospital treated patients with psoriasis
    • Poikolainen K, Karvonen J, Pukkala E. 1999. Excess mortality related to alcohol and smoking among hospital treated patients with psoriasis. Arch Dermatol, 135:1490-3.
    • (1999) Arch Dermatol , vol.135 , pp. 1490-1493
    • Poikolainen, K.1    Karvonen, J.2    Pukkala, E.3
  • 63
    • 33846185076 scopus 로고    scopus 로고
    • A follow up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological immunity
    • Poulalhon N, Begon E Lebbe C, et al. 2007. A follow up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological immunity. Br J Dermatol, 156;329-36.
    • (2007) Br J Dermatol , vol.156 , pp. 329-336
    • Poulalhon, N.1    Begon, E.2    Lebbe, C.3
  • 64
    • 0032872277 scopus 로고    scopus 로고
    • Psoriasis causes as much disability as other major medical diseases
    • Rapp SR, Feldman SR, Exum ML, et al. 1999. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol, 41:401-7.
    • (1999) J Am Acad Dermatol , vol.41 , pp. 401-407
    • Rapp, S.R.1    Feldman, S.R.2    Exum, M.L.3
  • 65
    • 38449110911 scopus 로고    scopus 로고
    • Brief communication: Characteristics of spontaneous cases of tuberculosis associated with Infliximab
    • Raval A, Akhavan-Toyserkani G, Brinker A et al. 2007. Brief communication: characteristics of spontaneous cases of tuberculosis associated with Infliximab. Ann Int Med, 147;699-702.
    • (2007) Ann Int Med , vol.147 , pp. 699-702
    • Raval, A.1    Akhavan-Toyserkani, G.2    Brinker, A.3
  • 66
    • 26644433889 scopus 로고    scopus 로고
    • Infliximab induction and maintenance for moderate-to-severe psoriasis: A phase III, multi centre, double-blind trial
    • Reich K, Nestle FO, Papp, K, et al. 2005. Infliximab induction and maintenance for moderate-to-severe psoriasis: a phase III, multi centre, double-blind trial. Lancet, 366:1367-74.
    • (2005) Lancet , vol.366 , pp. 1367-1374
    • Reich, K.1    Nestle, F.O.2    Papp, K.3
  • 67
    • 38349097035 scopus 로고    scopus 로고
    • Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
    • Rich P, Griffiths CE, Reich K, et al. 2008. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol, 58:224-31.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 224-231
    • Rich, P.1    Griffiths, C.E.2    Reich, K.3
  • 68
    • 47549099185 scopus 로고    scopus 로고
    • Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study
    • Rigopoulos D, Gregoriou S, Stratigos A, et al. 2008. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol, 159:453-6.
    • (2008) Br J Dermatol , vol.159 , pp. 453-456
    • Rigopoulos, D.1    Gregoriou, S.2    Stratigos, A.3
  • 69
    • 34250662578 scopus 로고    scopus 로고
    • Successful treatment of severe psoriatic arthritis with infliximab in an 11 year old child suffering from linear psoriasis along the lines of Blaschko
    • Rott S, Kuster RM, Mrowietz U. 2007. Successful treatment of severe psoriatic arthritis with infliximab in an 11 year old child suffering from linear psoriasis along the lines of Blaschko. Br J Dermatol, 157:191-2.
    • (2007) Br J Dermatol , vol.157 , pp. 191-192
    • Rott, S.1    Kuster, R.M.2    Mrowietz, U.3
  • 70
    • 51349119641 scopus 로고    scopus 로고
    • Long-term management of generalized ustular psoriasis with infliximab: Case series
    • Routhouska SB, Sheth PB, Korman NJ. 2008. Long-term management of generalized ustular psoriasis with infliximab: case series. J Cut Med Surg, 12:184-8.
    • (2008) J Cut Med Surg , vol.12 , pp. 184-188
    • Routhouska, S.B.1    Sheth, P.B.2    Korman, N.J.3
  • 71
    • 7044264854 scopus 로고    scopus 로고
    • A comprehensive review and evaluation of the side effects of tumour necrosis factor alpha blockers, etanercept, infliximab and adalimumab
    • Scheinfeld N. 2004. A comprehensive review and evaluation of the side effects of tumour necrosis factor alpha blockers, etanercept, infliximab and adalimumab. Dermatol Treat, 15:280-94.
    • (2004) Dermatol Treat , vol.15 , pp. 280-294
    • Scheinfeld, N.1
  • 72
    • 0022253623 scopus 로고
    • Psoriasis of the nail
    • Scher RK. 1985. Psoriasis of the nail. Dermatol Clin, 3:387-94.
    • (1985) Dermatol Clin , vol.3 , pp. 387-394
    • Scher, R.K.1
  • 73
    • 1542402063 scopus 로고    scopus 로고
    • Recalcitrant, generalized pustular psoriasis: Rapid and lasting therapeutic response to anti tumour necrosis factor-alpha antibody (infliximab)
    • Schinick K, Grabbe J. 2004. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to anti tumour necrosis factor-alpha antibody (infliximab). Br J Dermatol, 150:367.
    • (2004) Br J Dermatol , vol.150 , pp. 367
    • Schinick, K.1    Grabbe, J.2
  • 74
    • 61549138557 scopus 로고    scopus 로고
    • Scottish Medicines Consortium guidance on infliximab 100 mg powder for intravenous infusion (Remicade) No
    • Scottish Medicines Consortium guidance on infliximab 100 mg powder for intravenous infusion (Remicade) No (318/06) 2007.
    • (2007) , vol.318 , Issue.6
  • 75
    • 34548027771 scopus 로고    scopus 로고
    • Obesity, waist circurnference, weight change and the risk of psoriasis in women
    • Setty AR, Curhan G, Choi HK. 2007. Obesity, waist circurnference, weight change and the risk of psoriasis in women. Arch Intern Med, 167:1670-5.
    • (2007) Arch Intern Med , vol.167 , pp. 1670-1675
    • Setty, A.R.1    Curhan, G.2    Choi, H.K.3
  • 76
    • 24344471811 scopus 로고    scopus 로고
    • British Association of Dermatologists guideline for the use of biological interventions in psoriasis
    • Smith CH, Anstey AV, Barker, et al. 2005. British Association of Dermatologists guideline for the use of biological interventions in psoriasis. Br J Dermalol, 153:486-97.
    • (2005) Br J Dermalol , vol.153 , pp. 486-497
    • Smith, C.H.1    Anstey, A.V.2    Barker3
  • 77
    • 33747597605 scopus 로고    scopus 로고
    • Psoriasis and its management
    • Smith CH, Barker JN. 2006. Psoriasis and its management. BMJ, 333:380-4.
    • (2006) BMJ , vol.333 , pp. 380-384
    • Smith, C.H.1    Barker, J.N.2
  • 78
    • 34548590671 scopus 로고    scopus 로고
    • Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis
    • Takahashi MD, Castro LG, Romiti R. 2007. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol, 157:828-31.
    • (2007) Br J Dermatol , vol.157 , pp. 828-831
    • Takahashi, M.D.1    Castro, L.G.2    Romiti, R.3
  • 79
    • 0026501836 scopus 로고
    • The role of streptococcal infection in the initiation of guttate psoriasis
    • Telfer NR, Chalmers RJ, Whale K, et al. 1992. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol, 128:39-42.
    • (1992) Arch Dermatol , vol.128 , pp. 39-42
    • Telfer, N.R.1    Chalmers, R.J.2    Whale, K.3
  • 80
    • 24144450014 scopus 로고    scopus 로고
    • Successful treatment of Von Zumbush pustular psoriasis with infliximab
    • Trent JT, Kerdel FA. 2004. Successful treatment of Von Zumbush pustular psoriasis with infliximab. J Cut Med Surg, 8:224-8.
    • (2004) J Cut Med Surg , vol.8 , pp. 224-228
    • Trent, J.T.1    Kerdel, F.A.2
  • 81
    • 0036188666 scopus 로고    scopus 로고
    • Uyanik BS, Ari Z Omur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. 2002. Clin Chem Lab Med, 40:65-8.
    • Uyanik BS, Ari Z Omur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. 2002. Clin Chem Lab Med, 40:65-8.
  • 82
    • 0031014382 scopus 로고    scopus 로고
    • Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross react with keratin?
    • Valdimarsson H, Sigmundsdottir H, Jonsdottir I. 1997. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross react with keratin? Clin Exp Dermatol, 107(Supp 1):21-4.
    • (1997) Clin Exp Dermatol , vol.107 , Issue.SUPP 1 , pp. 21-24
    • Valdimarsson, H.1    Sigmundsdottir, H.2    Jonsdottir, I.3
  • 83
    • 61549111385 scopus 로고    scopus 로고
    • Biologic agents offer hope for psoriasis. Business briefing: European
    • Van de Kerkhof P. 2003. Biologic agents offer hope for psoriasis. Business briefing: European Pharmacotherapy. p 124-8.
    • (2003) Pharmacotherapy , pp. 124-128
    • Van de Kerkhof, P.1
  • 84
    • 38549131372 scopus 로고    scopus 로고
    • Infliximab in recalcitrant generalised pustular arthropathic psoriasis
    • Vieira Serrao V, Martins A, Lopes MJ. 2008. Infliximab in recalcitrant generalised pustular arthropathic psoriasis. Eur J Dermatol, 18:71-2.
    • (2008) Eur J Dermatol , vol.18 , pp. 71-72
    • Vieira Serrao, V.1    Martins, A.2    Lopes, M.J.3
  • 85
    • 33749255411 scopus 로고    scopus 로고
    • Sequential use of infliximab and etanercept in generalized pustular psoriasis
    • Weisenseel P, Prinz JC. 2006. Sequential use of infliximab and etanercept in generalized pustular psoriasis Cutis, 78:197-9.
    • (2006) Cutis , vol.78 , pp. 197-199
    • Weisenseel, P.1    Prinz, J.C.2
  • 86
    • 33644931095 scopus 로고    scopus 로고
    • Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    • Wolbink GJ, Vis M, Lems W, et al. 2006. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum, 54:711-5.
    • (2006) Arthritis Rheum , vol.54 , pp. 711-715
    • Wolbink, G.J.1    Vis, M.2    Lems, W.3
  • 87
    • 37549005087 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha inhibitor induced psoriasis or psoriasiform. exanthemata: First 120 cases from the literature including a series of six new patients
    • Wollina U, Hansel G, Koch A, et al. 2008. Tumour necrosis factor alpha inhibitor induced psoriasis or psoriasiform. exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol, 9:1-14.
    • (2008) Am J Clin Dermatol , vol.9 , pp. 1-14
    • Wollina, U.1    Hansel, G.2    Koch, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.